Skip to main content
. 2022 Feb 15;11(1):1–27.

Table 3.

Monoclonal antibody especially for breast cancer

Drug Mechanism Type Therapy Group Side effects FDA Approval REF.
Pertuzumab HER2/neu Humanized monoclonal antibody Metastatic HER2-positive breast cancer Risk of infection, Bruising and bleeding, Anemia, Diarrhea, Loss of appetite, Sore mouth Yes [244]
Trastuzumab HER2/neu Humanized monoclonal antibody breast cancer and stomach cancer flu-like symptoms (high temperature, chills, and mild pain), nausea, and diarrhea Yes [245]